Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2012) 120 (21): 2633.

https://doi.org/10.1182/blood.V120.21.2633.2633

Published: 2012

Journal Articles

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Michaela Rancea, Andreas Engert, MD, Peter Borchmann, MD, Bastian von Tresckow, MD, Teresa Halbsguth, MD, Karolin Behringer, MD, Diana Wongso, MD, Boris Böll, MD, Beate Klimm, MD, Indra Thielen, MD, Dennis A. Eichenauer, MD, Nicole Skoetz, MD

Blood (2012) 120 (21): 4230.

https://doi.org/10.1182/blood.V120.21.4230.4230

Published: 2012

Journal Articles

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Michael Fuchs, MD, Annette Pluetschow, Beate Klimm, MD, Teresa Halbsguth, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2011) 118 (21): 2711.

https://doi.org/10.1182/blood.V118.21.2711.2711

Published: 2011

Journal Articles

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Bastian von Tresckow, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Denissa Peine, Stefan Knop, MD, Mariele Goebeler, MD, Jens M. Chemnitz, MD, Michael Hallek, MD, Andreas Engert, MD, Kai Hübel, MD

Blood (2011) 118 (21): 3965.

https://doi.org/10.1182/blood.V118.21.3965.3965

Published: 2011

Journal Articles

Relapsed Hodgkin Lymphoma in Elderly Patients: A Comprehensive Analysis From the German Hodgkin Study Group (GHSG)

Boris Böll, MD, Helen Görgen, Nils Arndt, MD, Annette Plütschow, PhD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD, Ralph Naumann, MD, Peter Borchmann, MD

Blood (2011) 118 (21): 92.

https://doi.org/10.1182/blood.V118.21.92.92

Published: 2011

Journal Articles

PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG).

Boris Böll, MD, Teresa Halbsguth, MD, Helen Görgen, Henning Bredenfeld, MD, Hans Eich, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD

Blood (2010) 116 (21): 2827.

https://doi.org/10.1182/blood.V116.21.2827.2827

Published: 2010

Journal Articles

Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma.

Boris Böll, Michael Fuchs, Katrin S. Reiners, PhD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2010) 116 (21): 2828.

https://doi.org/10.1182/blood.V116.21.2828.2828

Published: 2010

Journal Articles

Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)

Boris Böll, MD, Helen Görgen, Michael Fuchs, Bastian von Tresckow, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2010) 116 (21): 418.

https://doi.org/10.1182/blood.V116.21.418.418

Published: 2010

Journal Articles

Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial

Bastian von Tresckow, M.D., Denissa Peine, Boris Böll, M.D., Dennis A Eichenauer, M.D., Elke Pogge von Strandmann, Ph.D., Stefan Knop, M.D., Marielle Goebeler, M.D., Michael Hallek, MD, Andreas Engert, M.D., Kai Hübel, M.D.

Blood (2008) 112 (11): 3686.

https://doi.org/10.1182/blood.V112.11.3686.3686

Published: 2008

Journal Articles

The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis

Boris Böll, Hinrich Hansen, Friederike Heuck, Katrin Reiners, Peter Borchmann, Achim Rothe, Andreas Engert, Elke Pogge von Strandmann

Blood (2005) 106 (5): 1839–1842.

https://doi.org/10.1182/blood-2005-01-0427

Published: 2005

NARROW

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Relapsed Hodgkin Lymphoma in Elderly Patients: A Comprehensive Analysis From the German Hodgkin Study Group (GHSG)

PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG).

Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma.

Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)

Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial

The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only